Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review
Background/aimHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with a higher risk of metastasis and poorer overall survival (OS) due to HER2 gene overexpression/amplification. Although anti-HER2 targeted therapy has shown survival benefits in HER2-positive advance...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1286392/full |
| _version_ | 1797463631807381504 |
|---|---|
| author | Yang Li Jingjiao Zhang Zhengang Cai Xue Gao Lina Zhang Zhi Lu Xiaojie Wang Peiyao Yu Jia Li Fengqi Fang |
| author_facet | Yang Li Jingjiao Zhang Zhengang Cai Xue Gao Lina Zhang Zhi Lu Xiaojie Wang Peiyao Yu Jia Li Fengqi Fang |
| author_sort | Yang Li |
| collection | DOAJ |
| description | Background/aimHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with a higher risk of metastasis and poorer overall survival (OS) due to HER2 gene overexpression/amplification. Although anti-HER2 targeted therapy has shown survival benefits in HER2-positive advanced breast cancer (ABC) patients, long-term treatment often leads to drug resistance, complicating further treatment options. RC48, an antibody-drug conjugate (ADC), combines the benefits of antibody targeting with the cytotoxic effects of a small molecule drug.Case reportWe present a case involving a female patient with HER2-positive ABC who developed drug resistance and disease progression following multi-line anti-HER2 targeted therapy. In this instance, RC48 exhibited anti-tumor activity in an ABC patient resistant to HER2-targeted therapy. After eight treatment cycles with 120 mg of RC48, the tumor size decreased and stabilized.ConclusionThis case report underscores the potential clinical value of RC48 as a promising treatment alternative for patients resistant to HER2 targeted therapies. |
| first_indexed | 2024-03-09T17:53:31Z |
| format | Article |
| id | doaj.art-a21bc32c89bb4d7bbe6c63c4459b0348 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-09T17:53:31Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-a21bc32c89bb4d7bbe6c63c4459b03482023-11-24T10:32:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-11-011310.3389/fonc.2023.12863921286392Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature reviewYang Li0Jingjiao Zhang1Zhengang Cai2Xue Gao3Lina Zhang4Zhi Lu5Xiaojie Wang6Peiyao Yu7Jia Li8Fengqi Fang9Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, ChinaDepartment of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, ChinaDepartment of Breast Surgery, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, ChinaDepartment of Pathology, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, ChinaImaging and Nuclear Medicine Department, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, ChinaNuclear Medicine Department, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, ChinaDepartment of Radiotherapy, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, ChinaDepartment of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, ChinaDepartment of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, ChinaDepartment of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, ChinaBackground/aimHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is associated with a higher risk of metastasis and poorer overall survival (OS) due to HER2 gene overexpression/amplification. Although anti-HER2 targeted therapy has shown survival benefits in HER2-positive advanced breast cancer (ABC) patients, long-term treatment often leads to drug resistance, complicating further treatment options. RC48, an antibody-drug conjugate (ADC), combines the benefits of antibody targeting with the cytotoxic effects of a small molecule drug.Case reportWe present a case involving a female patient with HER2-positive ABC who developed drug resistance and disease progression following multi-line anti-HER2 targeted therapy. In this instance, RC48 exhibited anti-tumor activity in an ABC patient resistant to HER2-targeted therapy. After eight treatment cycles with 120 mg of RC48, the tumor size decreased and stabilized.ConclusionThis case report underscores the potential clinical value of RC48 as a promising treatment alternative for patients resistant to HER2 targeted therapies.https://www.frontiersin.org/articles/10.3389/fonc.2023.1286392/fullDisitamab Vedotin (RC48)advanced breast cancerhuman epidermal growth factor receptor 2targeted therapytumor resistancecase report |
| spellingShingle | Yang Li Jingjiao Zhang Zhengang Cai Xue Gao Lina Zhang Zhi Lu Xiaojie Wang Peiyao Yu Jia Li Fengqi Fang Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review Frontiers in Oncology Disitamab Vedotin (RC48) advanced breast cancer human epidermal growth factor receptor 2 targeted therapy tumor resistance case report |
| title | Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review |
| title_full | Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review |
| title_fullStr | Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review |
| title_full_unstemmed | Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review |
| title_short | Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review |
| title_sort | disitamab vedotin rc48 for her2 positive advanced breast cancer a case report and literature review |
| topic | Disitamab Vedotin (RC48) advanced breast cancer human epidermal growth factor receptor 2 targeted therapy tumor resistance case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1286392/full |
| work_keys_str_mv | AT yangli disitamabvedotinrc48forher2positiveadvancedbreastcanceracasereportandliteraturereview AT jingjiaozhang disitamabvedotinrc48forher2positiveadvancedbreastcanceracasereportandliteraturereview AT zhengangcai disitamabvedotinrc48forher2positiveadvancedbreastcanceracasereportandliteraturereview AT xuegao disitamabvedotinrc48forher2positiveadvancedbreastcanceracasereportandliteraturereview AT linazhang disitamabvedotinrc48forher2positiveadvancedbreastcanceracasereportandliteraturereview AT zhilu disitamabvedotinrc48forher2positiveadvancedbreastcanceracasereportandliteraturereview AT xiaojiewang disitamabvedotinrc48forher2positiveadvancedbreastcanceracasereportandliteraturereview AT peiyaoyu disitamabvedotinrc48forher2positiveadvancedbreastcanceracasereportandliteraturereview AT jiali disitamabvedotinrc48forher2positiveadvancedbreastcanceracasereportandliteraturereview AT fengqifang disitamabvedotinrc48forher2positiveadvancedbreastcanceracasereportandliteraturereview |